Lambrolizumab

A humanized monoclonal IgG4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immunopotentiating activity. Upon administration, lambrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include PD-L1, which is expressed on antigen presenting cells (APCs) and overexpressed on certain cancer cells, and PD-L2, which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation through the suppression of the P13k/Akt pathway. (NCI Thesaurus)

YOU MAY ALSO LIKE

Lambert Eaton Myasthenic Syndrome

A rare autoimmune presynaptic disorder characterized by impairment of the impulse transmission at the neuromuscular junction. It affects predominantly the proximal muscles…

Lambda Z Time Upper Limit

The upper limit on timing values to be included in the calculation of Lambda z.

Lambda Z Time Lower Limit

The lower limit on timing values to be included in the calculation of Lambda z.

Lambda Z

The first order rate constant associated with the terminal (log-linear) portion of the curve.

Lambda Sutural Junction

The point of junction of the sagittal and lambdoid sutures of the skull.

Lambda

A mixing parameter typically giving a degree of smoothing used, or a relaxation parameter defining a rate of convergence.